PI Industries Q2: EBITDA Margin Fell From 29% to 14%, Half Through Gross Margin and Half Through Overheads

PI Industries reported consolidated revenue from operations of ₹17,018 mn for July-September 2026 against ₹18,723 mn a year earlier (down 9.1%, our arithmetic), EBITDA of ₹2,362 mn at a 14% margin against ₹5,434 mn at 29%, and profit for the quarter of ₹1,222 mn against ₹4,093 mn (down 70.1%, our arithmetic). The company's investor presentation attributes the gross-margin fall (49% against 57%) to higher input cost and "Pricing pressure due to El Nino & genericization", and the overhead rise to investment in new businesses, R&D, new-molecule launches and energy cost. On our arithmetic, about 7.8 points of the 15.1-point EBITDA-margin fall sit at gross margin and about 7.5 at overheads. The filings give no customer, contract or molecule-level numbers, so they cannot show whether the custom-synthesis moat held.

The idea in one sentence

If a custom-synthesis franchise were as hard to leave as its owner's slides say, a patent expiry on a customer's molecule should hurt volume and price only on that molecule; PI's quarter shows a margin that roughly halved, but only about half of the fall sits where the company puts genericization, so the quarter alone cannot be read as the moat breaking (our reading).

The fact that breaks the assumption

The headline says the margin fell from 29% to 14% and the company cites genericization. The statement says something narrower. Gross margin fell 8 points, from 57% to 49%. But overheads rose to ₹6,091 mn from ₹5,306 mn, up 14.8% (our arithmetic), while revenue fell 9.1%. As a share of revenue, overheads went from 28.3% to 35.8% (our arithmetic), a rise of 7.5 points. Gross profit fell ₹2,301 mn and overheads rose ₹785 mn, against an EBITDA fall of ₹3,072 mn (our arithmetic; the small remainder is the share of profit of associate and joint venture, ₹35 mn against ₹21 mn). Employee benefit expense rose 16.3% (₹2,565 mn against ₹2,205 mn) and other expense 14.3% (₹3,462 mn against ₹3,028 mn), both our arithmetic from [RS] p.8.

The June quarter shows the order in which the two legs arrived. In Q1 FY27 the deck gives a gross margin of 57%, the same as Q2 FY26's 57%, yet an EBITDA margin of 22% and overheads of ₹5,984 mn, 35.2% of revenue (our arithmetic). From the June to the September quarter, about 7.3 of the 7.8 points of EBITDA-margin fall came from gross margin and about 0.6 from overheads (our arithmetic). Put plainly, the overhead step was already in the June quarter and the gross-margin step arrived in September. The company does not describe the quarters this way; this is the statement read across its three columns.

One concrete thing, followed: "not actively passed through"

On slide 4 of [IP], under agchem exports, the company writes: "Cost escalation not actively passed through under current market conditions". It sits beside "Focus on volume growth post genericization through price optimisation". Follow that one sentence through the filings.

Exports revenue was ₹12,277 mn against ₹14,739 mn, a fall the deck prints as 16.7% (our arithmetic agrees: ₹2,462 mn lower). The text bullet on the same slide says agchem exports fell "~18%"; the two figures are different measures and the deck does not reconcile them (our reading: the chart's export line also carries non-agchem export revenue). Domestic revenue rose to ₹4,741 mn from ₹3,984 mn, up 19.0%. The company gives three reasons for the export fall on slide 3: "Lower demand", "Genericization" and "Pricing pressure".

The segment note in [RS] (Annexure I, p.13) then shows where the profit went. Agro chemicals, which the note says "includes Agchem exports (CSM), Domestic Agri Brands and Biologicals", earned a segment profit before tax of ₹2,473 mn against ₹5,907 mn on segment revenue of ₹16,280 mn against ₹18,092 mn. That is 15.2% of segment revenue against 32.6% (our arithmetic). The Pharma segment, which the note describes as contract research, development and manufacturing of active ingredients, starting materials and intermediates, made a segment loss of ₹601 mn against ₹819 mn, so the group's fall is in Agro chemicals, not Pharma. The segment note does not separate CSM from domestic brands and biologicals, so the CSM margin on its own is not in the filing.

The mechanism: what a custom-synthesis moat should and should not protect

Our reading of the structure: a contract manufacturer of an innovator's crop-protection molecule is hard to switch because the customer has registered the process and quality, and the supplier carries the process know-how. Its exposure is to the customer's product life cycle: when a molecule goes off patent, generic competitors enter, the innovator's volumes and prices come under pressure, and the supplier is asked to reprice. The company's own slides describe both halves.

For the franchise, [IP] says: "Top 5 worldwide in AgChem CSM" and "70%+ revenue from proprietary products" (slide 15; the deck does not define "proprietary"), "6+ decades with Global innovators" and "Zero conflicts till date" (slide 15), "Non conflicting business model" (slide 18), and, on slide 19, "Technology pioneer with technological and IP based interventions in global contract manufacturing" with "over 130 unit processes" in hazardous chemistry. Slide 12 says "20 molecules have been commercialized over the last few years" and "60+ molecules are currently in active pipeline with > 60% in advanced stages of development".

For the patent cycle, the deck says on slide 20 that PI has "Experience of successfully managing transition of products from patented to generic", in the description of its domestic distribution model. On slide 5 it lists "Soft demand and pricing pressure from genericization in global agrochemical industry" as a reason for the half-year export decline (about 15%; exports revenue ₹25,819 mn against ₹30,359 mn). The deck presents genericization as a condition of the global industry. It does not say which of PI's molecules or customers it touches, how much of PI's exports they are, or how much margin it cost.

That is the gap for a moat test. A switching-cost moat predicts that the customer stays; the filings show export revenue falling and gross margin falling, and the company ties both partly to genericization, but they give no customer count, concentration or renewal data. So the quarter is consistent with a moat that is being repriced, and also with one that is intact on volume and exposed on price (our reading); the documents do not separate the two.

The other half: overheads the company links to investment

The deck lists the overhead drivers as "Continued investments in Development of new businesses (6%) & R&D (2%)", "New molecule launch expenses (1%)" and "increase in energy cost (3%)" (slide 4; the brackets carry no stated unit). Elsewhere it says R&D investment was "up 102%" for the half-year to strengthen peptide discovery, and market and product development investment was "up 108%" in biologicals (slide 9). The Health Sciences business, which the company describes as "Investment in infrastructure for future growth", had a Pharma segment loss of ₹1,417 mn for the half-year ([RS] p.13; slide 13 prints a Health Sciences loss of ₹1,250 mn, post intercompany eliminations, so the two bases differ). Global biologicals grew "+250%" in the quarter (slide 3).

On our reading, this is the part of the margin fall that the company ties mainly to its own investment spending (energy cost is also on its list), not to the market, and the part a custom-synthesis moat does not explain either way: the group is paying to build biologicals, peptides, electronic chemicals and a pharma contract business while the older export line shrinks. The company's own line on slide 14 is "Margins to normalize once volatility subsides"; we cannot test it and do not rely on it.

Two more items in [RS] bear on the profit line, not the margin. Profit before tax fell 65.0% (₹1,840 mn against ₹5,253 mn, our arithmetic), but profit for the quarter fell 70.1%, because total tax was ₹618 mn, 33.6% of profit before tax, against ₹1,160 mn, 22.1% (our arithmetic); deferred tax was ₹164 mn against ₹25 mn. The company gives no reason. And standalone profit for the quarter was ₹2,071 mn against ₹4,911 mn (down 57.8%, our arithmetic) on standalone revenue of ₹15,335 mn against ₹17,526 mn, so the consolidated profit is ₹849 mn below the parent's (our arithmetic). The filings do not reconcile the gap. The review report (paragraph 6, [RS] p.15) says two subsidiaries (with their step-down subsidiaries, one associate and one joint venture) and one further step-down subsidiary had a total net loss after tax of ₹854 mn for the quarter, before consolidation adjustments, without naming them; the Pharma segment's loss was ₹601 mn ([RS] p.13).

BEAR CASE: where this breaks

• The half-and-half split is arithmetic, not cause. Overheads are partly fixed, so some of the 7.5-point rise is simply a smaller revenue base (our reading). The company's bracketed drivers have no unit, so we cannot say how much of the overhead rise is "new businesses" and how much is energy or launch cost. Reading the overhead rise as mainly investment-led is the company's account plus our reading; its list also includes energy cost.
• The strongest case against a moat reading is in the company's own words. In our reading, a customer that cannot easily leave should let a supplier pass cost through. The company says cost escalation is "not actively passed through", exports fell about 17 to 18%, and it is pursuing "volume growth post genericization through price optimisation". The deck lists "Lower demand" (slide 3) and "Soft demand and pricing pressure" (slide 5) beside price, so it does not say whether price or volume was the larger loss. The filings do not say whether the non-pass-through is contract terms or competition, and we have one quarter's comparison from two documents.
• The case for the franchise. Q1 FY27 gross margin was 57%, so the fall is one quarter old. Domestic revenue grew about 19% and global biologicals 250%. On the balance sheet, net working capital fell from 139 days (March 2026) to 121 days and "surplus cash net of Debt" is ₹35,737 mn ([IP] slide 6). Consolidated operating cash flow for the half-year was ₹8,899 mn against ₹2,476 mn a year earlier, helped by a ₹1,387 mn fall in trade receivables and much smaller increases in contract assets (₹291 mn against ₹4,540 mn) and inventories (₹41 mn against ₹2,286 mn) than a year earlier ([RS] pp.10-11), and H1 capex was ₹5,674 mn (company figure, slide 6). None of this shows the moat, but it shows the quarter did not strain the balance sheet.
• Review, not audit. The limited-review conclusion is not modified, but a review is "substantially less in scope than an audit" ([RS] p.14), other auditors reviewed some subsidiaries, and four subsidiaries' results were not reviewed by their own auditors and are, per management, not material.
• No call. The earnings call was scheduled for 5 Nov at 12:00 noon and no transcript was read. The reasons the company gives for pricing and pass-through may be expanded there; this piece cannot say.

Why it costs the reader something

A reader who takes "margin halved on genericization" as one cause will price the whole fall as the cost of an ageing molecule book. The statement splits it: about 7.8 points at gross margin, where input cost, El Nino and genericization sit by the company's account, and about 7.5 points at overheads, where the company says it is funding new businesses. Our reading: the first is a test of how well a custom-synthesis franchise holds price when a patent cycle turns; the second is a test of whether the new businesses earn their cost, and the filings give no return figure for them. What would let a reader separate the two is not in the documents: export revenue by molecule age or customer, and a split of the price and volume effect.

The concrete thing, again

"Cost escalation not actively passed through under current market conditions" is a short sentence on one slide. In a quarter when gross margin fell from 57% to 49%, exports revenue fell 16.7% and the Agro chemicals segment's profit before tax fell from ₹5,907 mn to ₹2,473 mn, it is the company's own record that the Agro chemicals segment's margin was not protected in the quarter (the segment also holds domestic brands and biologicals, so this is not a CSM-only measure). What the filings do not say is why: contract terms, competition, or a deliberate price cut to hold volume. Until a document gives customer, contract or molecule-level numbers, the custom-synthesis moat remains described and not measured.

Sources

• [RS] PI Industries, outcome of the board meeting, results and review reports, 4 Nov 2026 (NSE)
• [IP] PI Industries, Q2 FY27 earnings-call investor presentation, 4 Nov 2026 (NSE)
• Earlier Moat & Margin piece on a contract manufacturer's switching costs: Laurus Labs, Q2 CDMO mix and margin
• Today's filings in context: Daily filing digest, 4 Nov 2026

Educational research, not investment advice. Every figure above is drawn from PI Industries' own filings of 4 November 2026 (results and review reports, and the earnings-call investor presentation; no call transcript was read, the call being scheduled for 5 November), read from the primary documents on 5 November 2026; derived figures are our arithmetic, labelled as such. MoatSCORE: 5.54 (AMBER, first-pass), read live from the Moat Screener on 5 Nov 2026. No buy/sell recommendations, no price targets, no share prices. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.